HUP0100702A2 - Gyulladásgátló oxadiazolil-adenozin származékok, eljárás előállításukra és köztitermékeik - Google Patents

Gyulladásgátló oxadiazolil-adenozin származékok, eljárás előállításukra és köztitermékeik

Info

Publication number
HUP0100702A2
HUP0100702A2 HU0100702A HUP0100702A HUP0100702A2 HU P0100702 A2 HUP0100702 A2 HU P0100702A2 HU 0100702 A HU0100702 A HU 0100702A HU P0100702 A HUP0100702 A HU P0100702A HU P0100702 A2 HUP0100702 A2 HU P0100702A2
Authority
HU
Hungary
Prior art keywords
alkyl
compounds
ch2oh
arylalkyl
derivatives
Prior art date
Application number
HU0100702A
Other languages
English (en)
Inventor
David Bays
Chuen Chan
Caroline Mary Cook
Richard Peter Charles Cousins
Brian Cox
Hazel Joan Dyke
Frank Ellis
Joanna Victoria Geden
Stephen Swanson
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0100702(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en
Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HUP0100702A2 publication Critical patent/HUP0100702A2/hu
Publication of HUP0100702A3 publication Critical patent/HUP0100702A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Above=16;SpInterLn=1440;>(57) A találmány az (I) általános képletű 2-(purin-9-il)-tetrahidrofuran-3,4-diol származékokra és azok sóira ésszolvátjaira vonatkozik. Atalálmány tárgyát képezik emellett evegyületek előállítási eljárásai, a vegyületeket hatóanyagkénttartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazásagyulladásos betegségek gyógyításában. A vegyületek képletében R1 és R2egymástól függetlenül jellemzően cikloalkilcsoportot, hidrogénatomot,diariletil-, cikloalkil-alkil-, alkil-, arilalkil-, R4R5N-alkil-,alkil-CH(CH2OH)-, arilalkil-CH(CH2OH)-, arilalkil-C(CH2OH)2- csoportotjelent, R3 jelentése jellemzően metil-, etil-, -CH=CH2, n-propil-, -CH2-CH=CH2, -CH=CHCH3, izopropenil-, ciklopropil-, ciklopropenil-, -CH(OH)CH3, -(CH2)q halogéncsoport. Ó
HU0100702A 1998-02-14 1999-02-12 Anti inflammatory oxadiazolyl-adenozine derivatives, method for producing them and intermediates for them HUP0100702A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9803169.3A GB9803169D0 (en) 1998-02-14 1998-02-14 Chemical compounds
GBGB9813533.8A GB9813533D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (en) 1998-02-14 1999-02-12 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives

Publications (2)

Publication Number Publication Date
HUP0100702A2 true HUP0100702A2 (hu) 2002-01-28
HUP0100702A3 HUP0100702A3 (en) 2003-01-28

Family

ID=26313119

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100702A HUP0100702A3 (en) 1998-02-14 1999-02-12 Anti inflammatory oxadiazolyl-adenozine derivatives, method for producing them and intermediates for them

Country Status (32)

Country Link
US (1) US6610665B1 (hu)
EP (1) EP1056759B1 (hu)
JP (1) JP2002503669A (hu)
KR (1) KR20010082512A (hu)
AP (1) AP2000001881A0 (hu)
AR (1) AR017457A1 (hu)
AT (1) ATE223429T1 (hu)
AU (1) AU757156B2 (hu)
BR (1) BR9907886A (hu)
CA (1) CA2319009A1 (hu)
CO (1) CO4990969A1 (hu)
DE (1) DE69902758T2 (hu)
DK (1) DK1056759T3 (hu)
EA (1) EA200000759A1 (hu)
EE (1) EE200000358A (hu)
ES (1) ES2183516T3 (hu)
HK (1) HK1032062A1 (hu)
HR (1) HRP20000538A2 (hu)
HU (1) HUP0100702A3 (hu)
IL (1) IL137402A0 (hu)
IS (1) IS5576A (hu)
MA (1) MA27121A1 (hu)
NO (1) NO20004045L (hu)
NZ (1) NZ505812A (hu)
PE (1) PE20000270A1 (hu)
PL (1) PL342396A1 (hu)
PT (1) PT1056759E (hu)
SK (1) SK12002000A3 (hu)
SV (1) SV1999000016A (hu)
TR (1) TR200002355T2 (hu)
WO (1) WO1999041267A1 (hu)
YU (1) YU50800A (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB9930075D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007302263A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as P13K lipid kinase inhibitors
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
CA2711637A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
KR20140077916A (ko) 2011-09-15 2014-06-24 노파르티스 아게 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (es) * 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
AU750462B2 (en) * 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Also Published As

Publication number Publication date
CO4990969A1 (es) 2000-12-26
JP2002503669A (ja) 2002-02-05
EP1056759B1 (en) 2002-09-04
TR200002355T2 (tr) 2000-11-21
ES2183516T3 (es) 2003-03-16
EA200000759A1 (ru) 2001-04-23
DE69902758T2 (de) 2003-05-15
PL342396A1 (en) 2001-06-04
DE69902758D1 (de) 2002-10-10
HUP0100702A3 (en) 2003-01-28
IL137402A0 (en) 2001-07-24
SV1999000016A (es) 1999-10-27
AU757156B2 (en) 2003-02-06
EE200000358A (et) 2001-10-15
AR017457A1 (es) 2001-09-05
DK1056759T3 (da) 2003-01-06
US6610665B1 (en) 2003-08-26
PT1056759E (pt) 2003-01-31
ATE223429T1 (de) 2002-09-15
HRP20000538A2 (en) 2000-12-31
AP2000001881A0 (en) 2000-09-30
EP1056759A1 (en) 2000-12-06
AU2623599A (en) 1999-08-30
MA27121A1 (fr) 2005-01-03
HK1032062A1 (en) 2001-07-06
BR9907886A (pt) 2000-10-17
PE20000270A1 (es) 2000-05-20
YU50800A (sh) 2003-04-30
SK12002000A3 (sk) 2001-07-10
NZ505812A (en) 2002-03-01
NO20004045D0 (no) 2000-08-11
KR20010082512A (ko) 2001-08-30
CA2319009A1 (en) 1999-08-19
NO20004045L (no) 2000-08-11
IS5576A (is) 2000-07-25
WO1999041267A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
HUP0100702A2 (hu) Gyulladásgátló oxadiazolil-adenozin származékok, eljárás előállításukra és köztitermékeik
DE69912606D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
YU81000A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4 diola
HUP9900172A2 (hu) Idegrendszeri elváltozások kezelésére alkalmas 10-aciloxi-10,11-dihidrobenz/b,f/azepin-5-karboxamid, előállítása és ezt tartalmazó gyógyszerkészítmény
BG104729A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
HUP0002347A2 (hu) Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására
TR200100410T2 (tr) 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
HUP0105437A2 (hu) Új malonsavszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0100280A2 (hu) Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
HUP0400732A2 (hu) Gyógyászatilag hatékony uridin-észterek
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
HUP0203312A2 (hu) Farmakológiailag hatékony szulfonamidszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0102425A2 (hu) Gyomorsav-elválasztást gátló imidazo-piridin-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0004492A2 (hu) Fundális relaxációs tulajdonságokkal rendelkező benzodioxán-, benzofurán- vagy benzopirán-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
CA2146429A1 (en) 25-carboxylic acid derivatives in the vitamin d series, method of producing them, intermediate products for this method, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicines
IL178350A0 (en) Vitamin d derivatives
HUP0001760A2 (hu) Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására
HUP9800291A2 (hu) Amido-pirimidin-származékok alkalmazása a glükóz metabolizmus megromlásának inhibiálására szolgáló gyógyászati készítmények előállítására
HUP0204154A2 (hu) Új benzotiadiazin vegyületek, eljárás előállításukra és ezen vegyületeket tartalmazó gyógyszerkészítmények
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
HUP0401018A2 (hu) 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
HUP0004007A2 (hu) Új policiklusos azaindolszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények
ES2028838T3 (es) Procedimiento para la obtencion de nuevos derivados de 4,5-hidro-oxazoles.